Event Rates in Randomized Clinical Trials Evaluating Cardiovascular Interventions and Devices

Area of Science:

• Cardiovascular Medicine
• Clinical Trial Design
• Evidence-Based Medicine

Background:

• Randomized clinical trials (RCTs) are the cornerstone of evidence-based medicine.
• Accurate estimation of event rates is critical for the statistical power and validity of RCTs.
• Overestimation of event rates can lead to underpowered studies and inaccurate conclusions.

Purpose of the Study:

• To investigate the prevalence, extent, and impact of event rate overestimation in cardiovascular intervention and device RCTs.
• To compare estimated primary event rates with actual observed rates in the control groups.
• To assess the proportion of nonsignificant RCTs that could truly exclude a relevant treatment effect.

Main Methods:

• Analysis of 27 RCTs (19,436 patients) evaluating cardiovascular interventions and devices.
• Comparison of pre-trial estimated primary event rates with actual observed event rates in control groups.
• Evaluation of the conclusions of nonsignificant superiority trials.

Main Results:

• Event rates were overestimated in 74.1% (20/27) of included RCTs.
• A significant mean difference of -22.9% was observed between estimated and actual event rates.
• Overestimation was particularly notable in trials involving biodegradable polymer drug-eluting coronary stents and renal artery stenting.
• Only 21.4% (3/14) of nonsignificant superiority trials had truly negative conclusions.

Conclusions:

• Event rate overestimation is a frequent and impactful issue in cardiovascular RCTs.
• This phenomenon can compromise the statistical power of trials, potentially leading to false-negative results.
• Accurate event rate estimation is crucial for robust clinical trial design and reliable therapeutic assessments.